Arcturus Therapeutics Holdings Inc. (ARCT): Price and Financial Metrics


Arcturus Therapeutics Holdings Inc. (ARCT): $54.55

1.97 (+3.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ARCT POWR Grades


  • ARCT scores best on the Value dimension, with a Value rank ahead of 51.4% of US stocks.
  • ARCT's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • ARCT ranks lowest in Sentiment; there it ranks in the 6th percentile.

ARCT Stock Summary

  • ARCT's price/sales ratio is 159.13; that's higher than the P/S ratio of 97.54% of US stocks.
  • With a year-over-year growth in debt of 217.01%, Arcturus Therapeutics Holdings Inc's debt growth rate surpasses 95.92% of about US stocks.
  • In terms of volatility of its share price, ARCT is more volatile than 94.32% of stocks we're observing.
  • Stocks that are quantitatively similar to ARCT, based on their financial statements, market capitalization, and price volatility, are XENE, PTGX, SGMO, TTNP, and ENTA.
  • ARCT's SEC filings can be seen here. And to visit Arcturus Therapeutics Holdings Inc's official web site, go to www.arcturusrx.com.

ARCT Valuation Summary

  • In comparison to the median Healthcare stock, ARCT's price/earnings ratio is 124.38% lower, now standing at -8.9.
  • Over the past 96 months, ARCT's price/sales ratio has gone NA NA.
  • ARCT's EV/EBIT ratio has moved up 141.8 over the prior 96 months.

Below are key valuation metrics over time for ARCT.

Stock Date P/S P/B P/E EV/EBIT
ARCT 2021-08-31 165.9 4.7 -8.9 -6.6
ARCT 2021-08-30 162.4 4.6 -8.7 -6.4
ARCT 2021-08-27 171.6 4.9 -9.2 -6.9
ARCT 2021-08-26 165.6 4.7 -8.8 -6.6
ARCT 2021-08-25 161.2 4.6 -8.6 -6.4
ARCT 2021-08-24 155.1 4.4 -8.3 -6.0

ARCT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARCT has a Quality Grade of C, ranking ahead of 25.23% of graded US stocks.
  • ARCT's asset turnover comes in at 0.02 -- ranking 368th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ARCT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.020 1 -32.552
2021-03-31 0.025 1 -19.685
2020-12-31 0.037 1 -30.242
2020-09-30 0.066 1 -5.591
2020-06-30 0.115 1 -4.145
2020-03-31 0.244 1 -2.814

ARCT Price Target

For more insight on analysts targets of ARCT, see our ARCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $78.46 Average Broker Recommendation 1.93 (Hold)

ARCT Stock Price Chart Interactive Chart >

Price chart for ARCT

ARCT Price/Volume Stats

Current price $54.55 52-week high $129.71
Prev. close $52.58 52-week low $24.87
Day low $52.48 Volume 329,887
Day high $54.70 Avg. volume 914,673
50-day MA $46.72 Dividend yield N/A
200-day MA $49.86 Market Cap 1.44B

Arcturus Therapeutics Holdings Inc. (ARCT) Company Bio


Arcturus Therapeutics Ltd a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company was founded in 2008 and is based in Tel Aviv, Israel.


ARCT Latest News Stream


Event/Time News Detail
Loading, please wait...

ARCT Latest Social Stream


Loading social stream, please wait...

View Full ARCT Social Stream

Latest ARCT News From Around the Web

Below are the latest news stories about Arcturus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ARCT as an investment opportunity.

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

SAN DIEGO, September 22, 2021--Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

Yahoo | September 22, 2021

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (NASDAQ: XLRN) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) C4 Therapeutics, Inc. (NASDAQ: CCCC) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Corvus Pharmaceuticals, Inc. NASDAQ: CRVS) Fulcrum Therapeutics, Inc. (NASDAQ: FULC) IVERIC bio, Inc. (NASDAQ: ISEE) Leap Therapeutics, Inc. (NASDAQ: LPTX) Opiant Pharmaceuticals, Inc

Yahoo | September 22, 2021

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

SAN DIEGO, September 22, 2021--Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine

Yahoo | September 22, 2021

Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

SAN DIEGO, September 08, 2021--Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

Yahoo | September 8, 2021

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO, September 07, 2021--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Yahoo | September 7, 2021

Read More 'ARCT' Stories Here

ARCT Price Returns

1-mo 6.46%
3-mo 57.02%
6-mo 33.60%
1-year 40.05%
3-year 463.53%
5-year 67.59%
YTD 25.75%
2020 299.08%
2019 139.96%
2018 -43.02%
2017 -45.92%
2016 -66.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9425 seconds.